The biotechnology industry has emerged at the forefront as a vital industry harboring potential for innovation, economic development, and enhanced healthcare deliverables. Having flourished immensely, particularly during the pandemic, the industry attributes its resilience to cutting-edge breakthroughs and unrelenting efforts in fighting the fatal virus. The industry's stable demand further reinforces its vitality, positioning it sturdily for sustained growth in the foreseeable future.
Given this backdrop, I think fundamentally strong biotech stocks Gilead Sciences, Inc. (GILD), Regeneron Pharmaceuticals, Inc. (REGN), and United Therapeutics Corporation (UTHR) could be wise portfolio additions for August.
